NO753413L - - Google Patents
Info
- Publication number
- NO753413L NO753413L NO753413A NO753413A NO753413L NO 753413 L NO753413 L NO 753413L NO 753413 A NO753413 A NO 753413A NO 753413 A NO753413 A NO 753413A NO 753413 L NO753413 L NO 753413L
- Authority
- NO
- Norway
- Prior art keywords
- acid
- dibenzo
- solution
- ester
- evaporated
- Prior art date
Links
- 150000002148 esters Chemical class 0.000 claims description 16
- 150000003839 salts Chemical class 0.000 claims description 16
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 claims description 15
- 238000005984 hydrogenation reaction Methods 0.000 claims description 10
- 239000003054 catalyst Substances 0.000 claims description 9
- SMZOUWXMTYCWNB-UHFFFAOYSA-N 2-(2-methoxy-5-methylphenyl)ethanamine Chemical compound COC1=CC=C(C)C=C1CCN SMZOUWXMTYCWNB-UHFFFAOYSA-N 0.000 claims description 7
- NIXOWILDQLNWCW-UHFFFAOYSA-N 2-Propenoic acid Natural products OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 claims description 7
- 235000019260 propionic acid Nutrition 0.000 claims description 7
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 claims description 7
- 239000007858 starting material Substances 0.000 claims description 7
- 238000000034 method Methods 0.000 claims description 6
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 5
- 239000001257 hydrogen Substances 0.000 claims description 5
- 229910052739 hydrogen Inorganic materials 0.000 claims description 5
- KLEKHHIXJQPUQC-UHFFFAOYSA-N 2-(11-oxodibenzo[1,2-a:1',2'-e][7]annulen-3-yl)prop-2-enoic acid Chemical compound C1=CC2=CC=CC=C2C(=O)C2=CC=C(C(=C)C(=O)O)C=C21 KLEKHHIXJQPUQC-UHFFFAOYSA-N 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 3
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 27
- 239000000243 solution Substances 0.000 description 20
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 19
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 18
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 15
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 14
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 12
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 9
- 238000006243 chemical reaction Methods 0.000 description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 9
- 238000002844 melting Methods 0.000 description 8
- 230000008018 melting Effects 0.000 description 8
- 239000000203 mixture Substances 0.000 description 8
- 239000002904 solvent Substances 0.000 description 8
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 7
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 7
- 239000000047 product Substances 0.000 description 7
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 6
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 6
- PCLIMKBDDGJMGD-UHFFFAOYSA-N N-bromosuccinimide Chemical compound BrN1C(=O)CCC1=O PCLIMKBDDGJMGD-UHFFFAOYSA-N 0.000 description 6
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 6
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 6
- 150000001875 compounds Chemical class 0.000 description 6
- 238000002360 preparation method Methods 0.000 description 6
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Natural products CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 5
- YXHKONLOYHBTNS-UHFFFAOYSA-N Diazomethane Chemical compound C=[N+]=[N-] YXHKONLOYHBTNS-UHFFFAOYSA-N 0.000 description 5
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 5
- -1 n-amyl Chemical group 0.000 description 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- HUMNYLRZRPPJDN-UHFFFAOYSA-N benzaldehyde Chemical compound O=CC1=CC=CC=C1 HUMNYLRZRPPJDN-UHFFFAOYSA-N 0.000 description 4
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 4
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 4
- VRFBWIZDEHGFKI-UHFFFAOYSA-N 2-(2-phenylethyl)terephthalic acid Chemical compound OC(=O)C1=CC=C(C(O)=O)C(CCC=2C=CC=CC=2)=C1 VRFBWIZDEHGFKI-UHFFFAOYSA-N 0.000 description 3
- WGGHNGYOOFVVCG-VOTSOKGWSA-N 2-[(e)-2-phenylethenyl]terephthalic acid Chemical compound OC(=O)C1=CC=C(C(O)=O)C(\C=C\C=2C=CC=CC=2)=C1 WGGHNGYOOFVVCG-VOTSOKGWSA-N 0.000 description 3
- NIXOWILDQLNWCW-UHFFFAOYSA-M Acrylate Chemical compound [O-]C(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-M 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 3
- 206010061218 Inflammation Diseases 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- IDZYGHMGZHGNQF-UHFFFAOYSA-M [2,5-bis(methoxycarbonyl)phenyl]methyl-triphenylphosphanium;bromide Chemical compound [Br-].COC(=O)C1=CC=C(C(=O)OC)C(C[P+](C=2C=CC=CC=2)(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1 IDZYGHMGZHGNQF-UHFFFAOYSA-M 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 239000002585 base Substances 0.000 description 3
- XXTZHYXQVWRADW-UHFFFAOYSA-N diazomethanone Chemical compound [N]N=C=O XXTZHYXQVWRADW-UHFFFAOYSA-N 0.000 description 3
- UAOMVDZJSHZZME-UHFFFAOYSA-N diisopropylamine Chemical compound CC(C)NC(C)C UAOMVDZJSHZZME-UHFFFAOYSA-N 0.000 description 3
- UTIKNGRWJJKNBJ-UHFFFAOYSA-N dimethyl 2-(bromomethyl)benzene-1,4-dicarboxylate Chemical compound COC(=O)C1=CC=C(C(=O)OC)C(CBr)=C1 UTIKNGRWJJKNBJ-UHFFFAOYSA-N 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- 238000001953 recrystallisation Methods 0.000 description 3
- 229910052708 sodium Inorganic materials 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 3
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 2
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical compound CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 description 2
- UFMBOFGKHIXOTA-UHFFFAOYSA-N 2-methylterephthalic acid Chemical compound CC1=CC(C(O)=O)=CC=C1C(O)=O UFMBOFGKHIXOTA-UHFFFAOYSA-N 0.000 description 2
- MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 125000005396 acrylic acid ester group Chemical group 0.000 description 2
- 229910052783 alkali metal Inorganic materials 0.000 description 2
- TZCXTZWJZNENPQ-UHFFFAOYSA-L barium sulfate Chemical compound [Ba+2].[O-]S([O-])(=O)=O TZCXTZWJZNENPQ-UHFFFAOYSA-L 0.000 description 2
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 2
- 150000001732 carboxylic acid derivatives Chemical group 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- PJANXHGTPQOBST-QXMHVHEDSA-N cis-stilbene Chemical compound C=1C=CC=CC=1/C=C\C1=CC=CC=C1 PJANXHGTPQOBST-QXMHVHEDSA-N 0.000 description 2
- FNFJZXAWCAEGNI-UHFFFAOYSA-N cycloheptene-1-carboxylic acid Chemical compound OC(=O)C1=CCCCCC1 FNFJZXAWCAEGNI-UHFFFAOYSA-N 0.000 description 2
- DXIRJLBDSXBZCS-UHFFFAOYSA-N dimethyl 2-methylbenzene-1,4-dicarboxylate Chemical compound COC(=O)C1=CC=C(C(=O)OC)C(C)=C1 DXIRJLBDSXBZCS-UHFFFAOYSA-N 0.000 description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
- 238000001704 evaporation Methods 0.000 description 2
- 230000008020 evaporation Effects 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 230000002349 favourable effect Effects 0.000 description 2
- 210000003754 fetus Anatomy 0.000 description 2
- GNOIPBMMFNIUFM-UHFFFAOYSA-N hexamethylphosphoric triamide Chemical compound CN(C)P(=O)(N(C)C)N(C)C GNOIPBMMFNIUFM-UHFFFAOYSA-N 0.000 description 2
- KDCIHNCMPUBDKT-UHFFFAOYSA-N hexane;propan-2-one Chemical compound CC(C)=O.CCCCCC KDCIHNCMPUBDKT-UHFFFAOYSA-N 0.000 description 2
- 230000004968 inflammatory condition Effects 0.000 description 2
- 150000007529 inorganic bases Chemical class 0.000 description 2
- ZCSHNCUQKCANBX-UHFFFAOYSA-N lithium diisopropylamide Chemical compound [Li+].CC(C)[N-]C(C)C ZCSHNCUQKCANBX-UHFFFAOYSA-N 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 150000007530 organic bases Chemical class 0.000 description 2
- 239000012044 organic layer Substances 0.000 description 2
- 230000020477 pH reduction Effects 0.000 description 2
- QNGNSVIICDLXHT-UHFFFAOYSA-N para-ethylbenzaldehyde Natural products CCC1=CC=C(C=O)C=C1 QNGNSVIICDLXHT-UHFFFAOYSA-N 0.000 description 2
- 229920000137 polyphosphoric acid Polymers 0.000 description 2
- 230000035935 pregnancy Effects 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- 239000000741 silica gel Substances 0.000 description 2
- 229910002027 silica gel Inorganic materials 0.000 description 2
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 2
- FKXIHGGGPQKFMX-UHFFFAOYSA-N 11-oxodibenzo[1,2-a:1',2'-e][7]annulene-3-carbonyl chloride Chemical compound C1=CC2=CC=CC=C2C(=O)C2=CC=C(C(=O)Cl)C=C21 FKXIHGGGPQKFMX-UHFFFAOYSA-N 0.000 description 1
- LBEXHSXHRMXXGP-UHFFFAOYSA-N 11-oxodibenzo[1,2-a:1',2'-e][7]annulene-3-carboxylic acid Chemical compound C1=CC2=CC=CC=C2C(=O)C2=CC=C(C(=O)O)C=C21 LBEXHSXHRMXXGP-UHFFFAOYSA-N 0.000 description 1
- XUSWEPAQYWTNKX-UHFFFAOYSA-N 2-(11-oxodibenzo[1,2-a:1',2'-e][7]annulen-3-yl)acetic acid Chemical compound C1=CC2=CC=CC=C2C(=O)C2=CC=C(CC(=O)O)C=C21 XUSWEPAQYWTNKX-UHFFFAOYSA-N 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- HVPKMKCVHAWMFV-UHFFFAOYSA-N 7-(2-diazoacetyl)tricyclo[9.4.0.03,8]pentadeca-1(15),3(8),4,6,9,11,13-heptaen-2-one Chemical compound C1=CC2=CC=CC=C2C(=O)C2=C1C(C(=O)C=[N+]=[N-])=CC=C2 HVPKMKCVHAWMFV-UHFFFAOYSA-N 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- 238000006218 Arndt-Eistert homologation reaction Methods 0.000 description 1
- 208000010392 Bone Fractures Diseases 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- SNRUBQQJIBEYMU-UHFFFAOYSA-N Dodecane Natural products CCCCCCCCCCCC SNRUBQQJIBEYMU-UHFFFAOYSA-N 0.000 description 1
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical class NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 208000006670 Multiple fractures Diseases 0.000 description 1
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- KJTLSVCANCCWHF-UHFFFAOYSA-N Ruthenium Chemical compound [Ru] KJTLSVCANCCWHF-UHFFFAOYSA-N 0.000 description 1
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical class [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical class [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 208000010040 Sprains and Strains Diseases 0.000 description 1
- 206010044565 Tremor Diseases 0.000 description 1
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical class CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 1
- 239000003377 acid catalyst Substances 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 238000005904 alkaline hydrolysis reaction Methods 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000001754 anti-pyretic effect Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 229960001948 caffeine Drugs 0.000 description 1
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- OQNGCCWBHLEQFN-UHFFFAOYSA-N chloroform;hexane Chemical compound ClC(Cl)Cl.CCCCCC OQNGCCWBHLEQFN-UHFFFAOYSA-N 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 150000001879 copper Chemical class 0.000 description 1
- 125000002704 decyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 150000005690 diesters Chemical class 0.000 description 1
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
- 229940043279 diisopropylamine Drugs 0.000 description 1
- 125000003438 dodecyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 150000002168 ethanoic acid esters Chemical class 0.000 description 1
- 239000012259 ether extract Substances 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- ZDGGJQMSELMHLK-UHFFFAOYSA-N m-Trifluoromethylhippuric acid Chemical compound OC(=O)CNC(=O)C1=CC=CC(C(F)(F)F)=C1 ZDGGJQMSELMHLK-UHFFFAOYSA-N 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- OJURWUUOVGOHJZ-UHFFFAOYSA-N methyl 2-[(2-acetyloxyphenyl)methyl-[2-[(2-acetyloxyphenyl)methyl-(2-methoxy-2-oxoethyl)amino]ethyl]amino]acetate Chemical compound C=1C=CC=C(OC(C)=O)C=1CN(CC(=O)OC)CCN(CC(=O)OC)CC1=CC=CC=C1OC(C)=O OJURWUUOVGOHJZ-UHFFFAOYSA-N 0.000 description 1
- 150000004702 methyl esters Chemical class 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 229910052763 palladium Inorganic materials 0.000 description 1
- 125000000913 palmityl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 230000008707 rearrangement Effects 0.000 description 1
- 230000002040 relaxant effect Effects 0.000 description 1
- 229910052703 rhodium Inorganic materials 0.000 description 1
- 239000010948 rhodium Substances 0.000 description 1
- MHOVAHRLVXNVSD-UHFFFAOYSA-N rhodium atom Chemical compound [Rh] MHOVAHRLVXNVSD-UHFFFAOYSA-N 0.000 description 1
- QBERHIJABFXGRZ-UHFFFAOYSA-M rhodium;triphenylphosphane;chloride Chemical compound [Cl-].[Rh].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 QBERHIJABFXGRZ-UHFFFAOYSA-M 0.000 description 1
- 229910052707 ruthenium Inorganic materials 0.000 description 1
- CLDWGXZGFUNWKB-UHFFFAOYSA-M silver;benzoate Chemical compound [Ag+].[O-]C(=O)C1=CC=CC=C1 CLDWGXZGFUNWKB-UHFFFAOYSA-M 0.000 description 1
- 210000002460 smooth muscle Anatomy 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- GGCZERPQGJTIQP-UHFFFAOYSA-N sodium;9,10-dioxoanthracene-2-sulfonic acid Chemical compound [Na+].C1=CC=C2C(=O)C3=CC(S(=O)(=O)O)=CC=C3C(=O)C2=C1 GGCZERPQGJTIQP-UHFFFAOYSA-N 0.000 description 1
- 125000004079 stearyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- HXJUTPCZVOIRIF-UHFFFAOYSA-N sulfolane Chemical compound O=S1(=O)CCCC1 HXJUTPCZVOIRIF-UHFFFAOYSA-N 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
- 239000008096 xylene Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C59/40—Unsaturated compounds
- C07C59/76—Unsaturated compounds containing keto groups
- C07C59/86—Unsaturated compounds containing keto groups containing six-membered aromatic rings and other rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C61/00—Compounds having carboxyl groups bound to carbon atoms of rings other than six-membered aromatic rings
- C07C61/16—Unsaturated compounds
- C07C61/26—Unsaturated compounds having a carboxyl group bound to a seven-to-twelve-membered ring
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Description
Den foreliggende oppfinnelse vedrører en fremgangsmåte for fremstilling av 2-(5H-dibenzo[a,djcyklohepten-5-on-2-yl)-propionsyre og salter og estere av denne. Nærmere bestemt ved-rører oppfinnelsen en hydrogeneringsmetode for fremstilling av de forannevnte forbindelser fra den korresponderende acrylsyre, ester eller salt. The present invention relates to a method for the production of 2-(5H-dibenzo[a,djcyclohepten-5-on-2-yl)-propionic acid and its salts and esters. More specifically, the invention relates to a hydrogenation method for producing the aforementioned compounds from the corresponding acrylic acid, ester or salt.
Den substituerte propionsyre, estere og salter oppfinnelsen ve.l gjelder har anti-inflammatoriske, analgesiske og anti-pyretiske egenskaper. Følgelig er slike forbindelser og preparater som inneholder disse nyttige i behandlingen av The substituted propionic acid, esters and salts to which the invention applies have anti-inflammatory, analgesic and anti-pyretic properties. Accordingly, such compounds and preparations containing them are useful in the treatment of
betennelser såsom betennelsestilstander i muskel/skjelett-systemet, skjelett-leddene og andre vev f.eks. i behandling av betennelsestilstander såsom reumatisme, rystelse, oppflenging, artritis, benbrudd, post-traumatiske tilstander og ekte giEt. I de til-felle hvor de ovennevnte tilstander omfatter smerte og feber sammen med betennelse, er forbindelsene med'formel I nyttige for å lette disse tilstandene samtidig med betennelsen. inflammations such as inflammatory conditions in the muscle/skeletal system, skeletal joints and other tissues, e.g. in the treatment of inflammatory conditions such as rheumatism, tremors, sprains, arthritis, broken bones, post-traumatic conditions and true giEt. In those cases where the above conditions include pain and fever along with inflammation, the compounds of formula I are useful in alleviating these conditions along with the inflammation.
Forbindelsene ifølge oppfinnelsen er også avslap-pende midler for den glatte muskulatur.i livmoren og de er der-for nyttige som midler for å opprettholde svangerskapet i svangre pattedyr til fordel for.moren og/ellér fosteret inntil man fra et medisinsk synspunkt nanser avslutningen av svangerskapet for å være gunstig eller mere gunstig for moren og/eller fosteret. The compounds according to the invention are also relaxing agents for the smooth muscles in the uterus and they are therefore useful as agents for maintaining the pregnancy in pregnant mammals for the benefit of the mother and/or the fetus until, from a medical point of view, the termination of the pregnancy to be favorable or more favorable for the mother and/or the fetus.
Uttrykket "estere" av den foreliggende propionsyre eller den acrylsyre som danner utgangspunktet for den benyttes om de estere som er dannet av rette eller forgrenede alkanoler som har fra 1 til 20 karbonatomer, såsom f.eks. metyl, etyl, n-propyl, isopropyl, n-butyl, t-butyl, n-amyl, n-hexyl, octyl, The term "esters" of the present propionic acid or the acrylic acid that forms the starting point for it is used if the esters are formed from straight or branched alkanols having from 1 to 20 carbon atoms, such as e.g. methyl, ethyl, n-propyl, isopropyl, n-butyl, t-butyl, n-amyl, n-hexyl, octyl,
decyl, dodecyl, hexadecyl og octadecylestere og også om benzyl-estere. En foretrukket underklasse av estere er de som er dannet fra farmasøytisk akseptable, ikke-toksiske alkoholer. decyl, dodecyl, hexadecyl and octadecyl esters and also about benzyl esters. A preferred subclass of esters are those formed from pharmaceutically acceptable, non-toxic alcohols.
"Salter" av den foreliggende propionsyre og acrylsyre som danner utgangspunktet for den vedrører de salter som er fremstilt av uorganiske og organiske baser. -Salter som er dannet av. uorganiske baser omfatter alkalimetallsalter såsom natrium', kalanhm og litium; jordalkalimetallsalter såsom kalsium og magnesium; og også ammonium og koppersalter. De salter som er dannet av organiske baser omfatter etanolamin, dietylamin, tris(hydroksymetyl)aminometan, cholin, caffein og lysinsalter. En foretrukket uhdefcklasse av salter er de som er dannet av farmasøytiske akseptable, ikke-toksiske basér. "Salts" of the present propionic acid and acrylic acid which form the starting point for it relate to the salts which are prepared from inorganic and organic bases. -Salts formed from inorganic bases include alkali metal salts such as sodium, potassium and lithium; alkaline earth metal salts such as calcium and magnesium; and also ammonium and copper salts. The salts formed from organic bases include ethanolamine, diethylamine, tris(hydroxymethyl)aminomethane, choline, caffeine and lysine salts. A preferred uhdefc class of salts are those formed from pharmaceutically acceptable, non-toxic bases.
Fremgangsmåten ifølge den foreliggende oppfinnelse omfatter å hydrogenere 2-(5H-dibenzo(a,d)cyklohepten-5-on-2-yl)-acrylsyre eller en ester eller et salt. av denne for å frembringe den korresponderende propionsyre, ester eller salt. The method according to the present invention comprises hydrogenating 2-(5H-dibenzo(a,d)cyclohepten-5-on-2-yl)-acrylic acid or an ester or a salt. of this to produce the corresponding propionic acid, ester or salt.
Hydrogeneringen utføres ved å bringe acrylsyren, esteren eller saltet i kontakt med hydrogen i nærvær av en passende hydrogeneringskatalysator i et passende oppløsnings-? medium. The hydrogenation is carried out by bringing the acrylic acid, ester or salt into contact with hydrogen in the presence of a suitable hydrogenation catalyst in a suitable solvent. medium.
Passende hydrogeneringskatalysator for denne reaksjonen omfatter understøttede, ikke-understøttede eller oppløse-'lige metallkatalysatorer såsom f.eks. palladium, plåtinum, rodium, rutenium, tris(trifenylfosfin)klorrodium og lignende. Suitable hydrogenation catalysts for this reaction include supported, unsupported or soluble metal catalysts such as e.g. palladium, plåtinum, rhodium, ruthenium, tris(triphenylphosphine)chlororhodium and the like.
Passende katalysatorunderstøttere omfatter karbon, bariumsulfat og lignende. Suitable catalyst supports include carbon, barium sulfate and the like.
Reaksjonen utføres i et passende oppløsningsmiddel som f.eks. en flytende alkohol såsom metanol, etanol og lignende; The reaction is carried out in a suitable solvent such as e.g. a liquid alcohol such as methanol, ethanol and the like;
estere såsom.etylacetat; etere såsom dietyleter eller tetrahydrofuran; hydrokarboner såsom benzen, toluen eller xylen; esters such as ethyl acetate; ethers such as diethyl ether or tetrahydrofuran; hydrocarbons such as benzene, toluene or xylene;
dimetylformamid eller blandinger av disse med vann. dimethylformamide or mixtures thereof with water.
Reaksjonstemperaturen er ikke meget kritisk. For eksempel kan reaksjonen utføres ved temperaturer fra ca. ,0°C The reaction temperature is not very critical. For example, the reaction can be carried out at temperatures from approx. .0°C
til kokepunktet for det angjeldende oppløsningsmiddel (som kan to the boiling point of the solvent in question (which can
heves over sin normale verdi avhengig av det benyttede trykk). is raised above its normal value depending on the pressure used).
Reaksjonen utføres inntil hydrogeneringen i store trekk er av-sluttet, dvs. inntil en molekvivalent hydrogen er blitt absorbert noe som vanligvis tar fra 15 minutter til ca. 48 timer. Presset er ikke særlig kritisk og man kan arbeide fra atmosfære-trykk til ca. 10 atmosfærer. • En foretrukket hydrogenering omfatter anvendelse av palladium på kullkatalysator ved værelsetemperatur og vanlig trykk i et oppløsningsmiddel såsom dimetylformamid. The reaction is carried out until the hydrogenation is largely complete, i.e. until a molar equivalent of hydrogen has been absorbed, which usually takes from 15 minutes to approx. 48 hours. The pressure is not particularly critical and you can work from atmospheric pressure to approx. 10 atmospheres. • A preferred hydrogenation involves the use of palladium on charcoal catalyst at room temperature and normal pressure in a solvent such as dimethylformamide.
Det hydrogenerte produkt isoleres vanligvis ved vanlige fremgangsmåter såsom filtrering for å fjerne hydroge-neringskatalysatoren, fulgt av fordampning av oppløsningsmidlet. The hydrogenated product is usually isolated by conventional methods such as filtration to remove the hydrogenation catalyst, followed by evaporation of the solvent.
-Kromatografi og/eller rekrystallisering av sluttproduktet fra -Chromatography and/or recrystallization of the end product from
et passende oppløsningsmiddel er vanligvis nyttig for å rense sluttproduktet. a suitable solvent is usually useful to purify the final product.
Når man utfører hydrogeneringsreaksjonen som be-skrevet ovenfor, vil syren som utgjør utgangsmaterialet gi et syreprodukt, et salt vil gi et saltprodukt og en ester i utgangsmaterialet vil gi et esterprodukt. When carrying out the hydrogenation reaction as described above, the acid which forms the starting material will give an acid product, a salt will give a salt product and an ester in the starting material will give an ester product.
Den acrylsyre, estere og salter som anvendes som utgangsmateriale kan fremstilles på følgende måte:-Utgangsmaterialet (dvs. 5-oxo-5H-dibenzo(a,d)cyklo-hepten-2-karboksylsyre) fremstilles ved å esterifisere 2-metyltereftalsyre med metanol- i nærvær av en syrekatalysator for å tilveiebringe den. korresponderende dimetylester, som i sin tur, omsettes med N-bromsuccinimid for å gi 2-brommetyltereftalsyre-dimetylester. Denne diester omsettes med trifenylfosfin for å gi '2,5-bis(karbometoksy)benzyltrifenylfosfoniumbromid som be-handles med benzaldehyd og diåzabicyklononen for etter alkalisk hydrolyse å gi cis og trans-stilben 2,5-dikarboksylsyre. Hydrogenering a<y>den siste forbindelse med hydrogen over en 5 f°palladium på kullkatalysator-gir 2-(2-fenetyl)tereftalsyre. Behandling med polyfosforsyre gir 5-°xo-5.H-dibenzo £a,d]cyklo-héptan-2-karboksylsyre som kan rekrystalliseres fra vandig dimetylformamid. The acrylic acid, esters and salts used as starting material can be prepared in the following way: - The starting material (i.e. 5-oxo-5H-dibenzo(a,d)cyclo-heptene-2-carboxylic acid) is prepared by esterifying 2-methylterephthalic acid with methanol - in the presence of an acid catalyst to provide it. corresponding dimethyl ester, which in turn reacts with N-bromosuccinimide to give 2-bromomethylterephthalic acid dimethyl ester. This diester is reacted with triphenylphosphine to give 2,5-bis(carbomethoxy)benzyltriphenylphosphonium bromide which is treated with benzaldehyde and the diazabicyclonone to give, after alkaline hydrolysis, cis and trans-stilbene 2,5-dicarboxylic acid. Hydrogenation of the latter compound with hydrogen over a 5 f°palladium on charcoal catalyst gives 2-(2-phenethyl)terephthalic acid. Treatment with polyphosphoric acid gives 5-°xo-5.H-dibenzo £a,d]cycloheptane-2-carboxylic acid which can be recrystallized from aqueous dimethylformamide.
5-oxo"5H-diben-;zo (a,dj cyklohepten-2-karboksylsyre fremstilles ved etterfølgende behandling av 5-oxo-5H-dibenzo[a,dj-cykloheptan-2-karboksylsyre med diazometan, N-bromsuccinimid og dimetylformamid/diazabicyklononen fulgt av base hydrolyse og surgjøring for å tilveiebringe 5-°xo-5H-dibenzo(å,d)cyklohepten-2-karboksylsyre. 5-oxo"5H-dibenzo-;zo (a,dj cycloheptene-2-carboxylic acid is prepared by subsequent treatment of 5-oxo-5H-dibenzo[a,dj-cycloheptane-2-carboxylic acid with diazomethane, N-bromosuccinimide and dimethylformamide/ the diazabicyclonone followed by base hydrolysis and acidification to provide 5-α-xo-5H-dibenzo(α,d)cycloheptene-2-carboxylic acid.
Karboksylsyrekjeden av 2-karboksylsyreforbindelsen som er utgangsmaterialet forlenges til eddiksyreforbindelsen ved å utføre en vanlig Arndt-Eistert-reaksjon som omfatter omdanning av karboksylsyren til sitt syreklorid med thionylklorid, omsetning av syrekloridet med diazometan for 'å danne et diazoketon og rearrangerihg av diazoketonet ved påvirkning av et sølvsalt i nærvær av en alkohol for å gi den korresponderende 2-eddiksyre-ester som kan hydrolyseres til fri eddiksyre. The carboxylic acid chain of the 2-carboxylic acid compound which is the starting material is extended to the acetic acid compound by carrying out a standard Arndt-Eistert reaction which comprises conversion of the carboxylic acid to its acid chloride with thionyl chloride, reaction of the acid chloride with diazomethane to form a diazo ketone and rearrangement of the diazo ketone by the action of a silver salt in the presence of an alcohol to give the corresponding 2-acetic acid ester which can be hydrolyzed to free acetic acid.
Acrylsyreesteren kan fremstilles ved å omsette eddiksyreesteren med et alkalimetalldialkylamid såsom litium-diisopropylamid i et oppløsningsmiddel såsom tetrahydrofuran, hexametylfosforamid og lignende og deretter med formaldehyd. Acrylsyreesteren kan hydrolyseres med en base for å danne den korresponderende acrylsyre eller et salt av denne. The acrylic acid ester can be prepared by reacting the acetic acid ester with an alkali metal dialkylamide such as lithium diisopropylamide in a solvent such as tetrahydrofuran, hexamethylphosphoramide and the like and then with formaldehyde. The acrylic acid ester can be hydrolyzed with a base to form the corresponding acrylic acid or a salt thereof.
De følgende eksempler illustrerer foretrukne ut-førelser av fremgangsmåtene ifølge oppfinnelsen. Disse eksemplene må ikke oppfattes som begrensende i omfang eller i innhold av oppfinnelsen på noen måte.. Utbyttene av produktene varierer, avhengig av valg av utgangsmaterialet, reagenser, reaksjons-betingelser og fremgangsmåte.. Utbyttene ligger imidlertid vanligvis i området fra 10 til 70 prosent. The following examples illustrate preferred embodiments of the methods according to the invention. These examples must not be understood as limiting the scope or content of the invention in any way. The yields of the products vary, depending on the choice of starting material, reagents, reaction conditions and method. However, the yields are usually in the range from 10 to 70 percent .
Preparat 1 Preparation 1
I48 g 2-metyltereftalsyre kokes under tilbakeløp i 24 timer i 750-ml tørr metanol som inneholder 30 ml svovelsyre. Oppløsningen avkjøles, helles over i vann og ekstraheres med eter. Ekstraktet vaskes, tørkes og fordampes og gir dimetyl-2-metyltereftalat. 148 g of 2-methylterephthalic acid is refluxed for 24 hours in 750 ml of dry methanol containing 30 ml of sulfuric acid. The solution is cooled, poured into water and extracted with ether. The extract is washed, dried and evaporated to give dimethyl-2-methylterephthalate.
88 g dimetyl-2-metyltereftalat i 1000 ml karbontetraklorid som inneholder 89 g (1 eq.) N-bromsuccinimid kokes under tilbakeløp i 3 timer under anvendelse av en varm .lampe. Oppløsningen avkjøles, filtreres og fordampes til tørrhet og 88 g of dimethyl-2-methylterephthalate in 1000 ml of carbon tetrachloride containing 89 g (1 eq.) of N-bromosuccinimide is refluxed for 3 hours using a hot lamp. The solution is cooled, filtered and evaporated to dryness and
gir dimetyl-2-brommetyltereftalat. gives dimethyl-2-bromomethylterephthalate.
25,7 gdimetyl-2-brommetyltereftalat kokes under tilbakeløp i 25O ml acetonitril som inneholder 26,2 g (1 eq.) trifenylfosfin i 4 timer. Oppløsningen avkjøles og fortynnes 25.7 g of dimethyl-2-bromomethyl terephthalate is refluxed in 250 ml of acetonitrile containing 26.2 g (1 eq.) of triphenylphosphine for 4 hours. The solution is cooled and diluted
med 1250 ml eter hvoretter 2,5-bis(karbometoksy)-benzyltrifenyl-fosfoniumbromid utfelles og frafiltreres og tørkes under vakuum. with 1250 ml of ether, after which 2,5-bis(carbomethoxy)-benzyltriphenyl-phosphonium bromide is precipitated and filtered off and dried under vacuum.
51,9 g 2,5-bis(karbometoksy)-benzyltrifenylfosfonium-bromid og 10,6 g benzaldehyd omrøres i ^ 00 ml acetonitril og 51.9 g of 2,5-bis(carbomethoxy)-benzyltriphenylphosphonium bromide and 10.6 g of benzaldehyde are stirred in ^ 00 ml of acetonitrile and
12,4 g diazabicyklononen tilsettes. Blandingen oppvarmes kort til tilbakeløp, hvoretter den avkjøles og fordampes til en olje. Oljen oppløses i etylacetat og oppløsningen vaskes med fortynnet saltsyre, tørkes og fordampes. Residuet kokes under tilbakeløp i 12 timer i en oppløsning av 20 g kaliumhydroksyd i 200 ml vann og 50 ml metanol. Oppløsningen avkjøles og ekstraheres med kloroform. Den vandige oppløsning surgjøres med fortynnet saltsyre og den utfelte cis og trans stilben-2,5-dikarboksylsyre frafiltreres og tørkes. 12.4 g of the diazabicyclonon are added. The mixture is heated briefly to reflux, after which it is cooled and evaporated to an oil. The oil is dissolved in ethyl acetate and the solution is washed with dilute hydrochloric acid, dried and evaporated. The residue is refluxed for 12 hours in a solution of 20 g of potassium hydroxide in 200 ml of water and 50 ml of methanol. The solution is cooled and extracted with chloroform. The aqueous solution is acidified with dilute hydrochloric acid and the precipitated cis and trans stilbene-2,5-dicarboxylic acid is filtered off and dried.
23,6 g cis og trans -stilben-2,5-dikarboksylsyre oppløses i 100 ml dimetylformamid som inneholder 500 mg 5 % palladium på kull og hydrogeneres i 2 timer. Oppløsningen filtreres og fordampes til tørrhet og gir et urenset produkt som etter rekrystallisering fra vandig etanol gir 2-(2-fenetyl)-tereftalsyre. 23.6 g of cis and trans -stilbene-2,5-dicarboxylic acid are dissolved in 100 ml of dimethylformamide containing 500 mg of 5% palladium on charcoal and hydrogenated for 2 hours. The solution is filtered and evaporated to dryness and gives an impure product which, after recrystallization from aqueous ethanol, gives 2-(2-phenethyl)-terephthalic acid.
23,8. g 2-(2-fenetyl)tereftalsyre oppløses i 200 ml sulfolan ved 130°C og 150 ml polyfosforsyre tilsettes under om-røring. Blandingen omrøres ved 130°C i 4 timer, og helles deretter over i 1000 ml vann..Produktet frafiltreres og rekrystalliseres fra vandig dimetylformamid og gir 5-ox°-5H-dibenzo-(a,djcykloheptan-2-karboksylsyre (smeltepunkt 203-204<G>C). 23.8. g of 2-(2-phenethyl)terephthalic acid is dissolved in 200 ml of sulfolane at 130°C and 150 ml of polyphosphoric acid is added while stirring. The mixture is stirred at 130°C for 4 hours, and then poured into 1000 ml of water. The product is filtered off and recrystallized from aqueous dimethylformamide to give 5-ox°-5H-dibenzo-(a,djcycloheptane-2-carboxylic acid (melting point 203- 204<G>C).
Preparat 2 Preparation 2
5,0 g 5-oxo-5H-dibenzo(a,dJcykloheptan-2-karboksyl-syre (fremstilt i preparat 1 ovenfor) suspenderes i 50 ml dioxan, tilsettes til et overskudd av diazometan oppløst.i eter og om-røres inntil oppløsningen er fullstendig..Oppløsningen fordampes til tørrhet og gir 2-karbometoksy-5-oxo-5H-dibenzo(a,dJcyklo-heptan. 5.0 g of 5-oxo-5H-dibenzo(a,d)cycloheptane-2-carboxylic acid (prepared in preparation 1 above) is suspended in 50 ml of dioxane, added to an excess of diazomethane dissolved in ether and stirred until the solution is complete.. The solution is evaporated to dryness and gives 2-carbomethoxy-5-oxo-5H-dibenzo(a,dJcycloheptane.
4,68 g 2-karbometoksy-i|-oxo-5H-dibenzo(a,dJ cyklo-heptan kokes under tilbakeløp i 100 ml karbontetraklorid som inneholder .3,56 g (1 eq.) N-bromsuccinimid samtidig som opp-løsningen bestråles med en 100 watts glødelampe. Etter 2 timer avkjøles oppløsningen, filtreres og fordampes til tørrhet. Residuet oppløses i JO ml, dimetylformamid og 2,48 g (1 eq.) The solution irradiated with a 100 watt incandescent lamp. After 2 hours the solution is cooled, filtered and evaporated to dryness. The residue is dissolved in JO ml, dimethylformamide and 2.48 g (1 eq.)
l,5-diazabicyklo-(3>4>OJnonen-5 tilsettes. Blandingen oppvarmes kort til 60°C, og vann og etylacetat tilsettes. Det organiske lag vaskes med fortynnet saltsyre og vann, og tørkes og fordampes og gir 2-karbometoksy-5-pxo-5H-dibenzo(a,d)cyklohepten. Hydro- 1,5-diazabicyclo-(3>4>OJnonene-5) is added. The mixture is heated briefly to 60°C, and water and ethyl acetate are added. The organic layer is washed with dilute hydrochloric acid and water, and dried and evaporated to give 2-carbomethoxy- 5-pxo-5H-dibenzo(a,d)cycloheptene Hydro-
lyse. i 8 til 1 vandig metanol: 5$ kaliumhydroksyd, fulgt av surgjøring med fortynnet saltsyre gir 5-oxo-5H-dibenzo(a,dJ-cyklohepten-2-karboksylsyre (smeltepunkt 26l-262°C). bright. in 8 to 1 aqueous methanol: 5$ potassium hydroxide, followed by acidification with dilute hydrochloric acid gives 5-oxo-5H-dibenzo(a,dJ-cycloheptene-2-carboxylic acid (m.p. 26l-262°C).
. Preparat . Preparation
22 g 5-oxo-5H-dibenzofa.,dj cyklohepten-2-karboksyl-syre omrøres i 200 ml kloroform, ^ 0 ml thionylklorid og 1 ml dimetylformamid i 8 timer. Blandingen fordampes til tørrhet og residuet rekrystalliseres fra acetonitril og gir 2-klor-formyl-5-oxo-5H-dibenzo(a,d)cyklohepten. Dette oppløses i. 22 g of 5-oxo-5H-dibenzopha.,dj cycloheptene-2-carboxylic acid is stirred in 200 ml of chloroform, ^0 ml of thionyl chloride and 1 ml of dimethylformamide for 8 hours. The mixture is evaporated to dryness and the residue is recrystallized from acetonitrile to give 2-chloro-formyl-5-oxo-5H-dibenzo(a,d)cycloheptene. This dissolves in
200 ml kloroform og tilsettes til et 3-ganger overskudd av diazometan i eter ved 0°C. Blandingen hensettes ved 0°C i 12 200 ml of chloroform and added to a 3-fold excess of diazomethane in ether at 0°C. The mixture is left at 0°C for 12
timer og fordampes til tørrhet. Residuet rekrystalliseres fra acetonitril og gir 2-diazoacetyl-5-oxo-5H-dibenzo(a,d)cyklo-hepten. Diazoketonen oppvarmes til tilbakeløp i 250 ml etanol og en mettet trietylamin-oppløsning av 2 g sølvbenzoat tilsettes . langsomt inntil gassutviklingen opphører. Oppløsningen avkjøles, filtreres og fordampes og gir etyl(5-oxo-5H-dibenzo(a,djcyklo-hepten-2-yl)acetat. Denne esteren kokes under tilbakeløp i 5 f° vandig kaliumhydroksyd i 12 timer. Oppløsningen avkjøles, sur-gjøres med fortynnet saltsyre og ekstraheres med eter..Eter-ékstraktet tørkes og fordampes og.gir (5-oxo-5H-dibenzo(a,d) - cyklohepten-2-yl)eddiksyre som kan rekrystalliseres fra aceton-hexan (smeltepunkt.148-149?5°C). hours and evaporated to dryness. The residue is recrystallized from acetonitrile and gives 2-diazoacetyl-5-oxo-5H-dibenzo(a,d)cycloheptene. The diazoketone is heated to reflux in 250 ml of ethanol and a saturated triethylamine solution of 2 g of silver benzoate is added. slowly until gas development ceases. The solution is cooled, filtered and evaporated to give ethyl (5-oxo-5H-dibenzo(a,djcyclo-hepten-2-yl)acetate. This ester is refluxed in 5 f° aqueous potassium hydroxide for 12 hours. The solution is cooled, acid- is done with dilute hydrochloric acid and extracted with ether. The ether extract is dried and evaporated and gives (5-oxo-5H-dibenzo(a,d)-cyclohepten-2-yl)acetic acid which can be recrystallized from acetone-hexane (melting point. 148-149?5°C).
Metylesteren fremstilles ved behandling av den fri syre i dioxan med overskudd av diazometan i eter. The methyl ester is produced by treating the free acid in dioxane with an excess of diazomethane in ether.
Preparat. 4 Preparation. 4
1,25 ml 1,6 molar n-butyllitium i hexan tilsettes 1.25 ml of 1.6 molar n-butyllithium in hexane is added
til en oppløsning av 0,280 ml diisopropylamin i 30 ml tetrahydrofuran. -Oppløsningen avkjøles til -80°C og 0,55^ g metyl(5-0x0-5H-dibenzo(a,djcyklohepten-2-yl)acetat tilsettes, Etter 10 minutter tilsettes 0,38 ml hexametylfosforsyretriamid. -Kjølebadet fjernes og formaldehyddamp, medført av en nitrogenstrøm, passerer over oppløsningen inntil den blir fargeløs. Vann og eter tilsettes og det organiske lag vaskes med fortynnet saltsyre, mettet natriumkloridoppløsning hvoretter det tørkes og fordampes. Residuet kromatograferes på 10 g silikagel, eluering med hexan:etylacetat (5^1) for å isolere metyl 2-(5-oxo-5H-dibenzofa,d]cyklo-hepten-2-yl)acrylat (smeltepunkt 153-156°C). 0,02 g av denne to a solution of 0.280 ml of diisopropylamine in 30 ml of tetrahydrofuran. -The solution is cooled to -80°C and 0.55 g of methyl(5-0x0-5H-dibenzo(a,djcyclohepten-2-yl)acetate is added. After 10 minutes, 0.38 ml of hexamethylphosphoric acid triamide is added. -The cooling bath is removed and formaldehyde vapor , entrained by a stream of nitrogen, is passed over the solution until it becomes colorless. Water and ether are added and the organic layer is washed with dilute hydrochloric acid, saturated sodium chloride solution, then dried and evaporated. The residue is chromatographed on 10 g of silica gel, eluting with hexane:ethyl acetate (5^ 1) to isolate methyl 2-(5-oxo-5H-dibenzopha,d]cyclo-hepten-2-yl)acrylate (melting point 153-156°C). 0.02 g of this
forbindelse kokes under tilbakeløp under nitrogen i 5 ml vann, compound is refluxed under nitrogen in 5 ml of water,
2 ml etanol og 0,5 ml mettet natriumkarbonatoppløsning i 4 timer. Blandingen avkjøles, vaskes med eter og surgjøres med fortynnet saltsyre, hvoretter den ekstraheres med etylacetat og ekstraktet tørkes og fordampes tog gir 2-(5-oxo-5H-dibenzo(a,d)cyklohepten-2-yl)acrylsyre (smeltepunkt 232-235°C). 2 ml ethanol and 0.5 ml saturated sodium carbonate solution for 4 hours. The mixture is cooled, washed with ether and acidified with dilute hydrochloric acid, after which it is extracted with ethyl acetate and the extract is dried and evaporated to give 2-(5-oxo-5H-dibenzo(a,d)cyclohepten-2-yl)acrylic acid (melting point 232- 235°C).
Dette kan omdannes til natriumsaltet ved omsetning med en ekvivalent natriumbikarbonat i vann, fordampning av oppløsningsmidlet og rekrystallisering. This can be converted to the sodium salt by reaction with an equivalent of sodium bicarbonate in water, evaporation of the solvent and recrystallization.
Eksempel 1 Example 1
1,38 g 2-(5H-dibenzo(a,djcyklohepten-5-on-2-yl)-acrylsyre oppløses i 25. ml dimetylformamid som inneholder 0,05 S 5 fo palladium på kull katalysator. Blandingen omrøres i en hydrogeriåtmosfære ved 26°C og jSf mm Hg trykk'inntil 60 ml (1 molekvivalent) er blitt absorbert. Oppløsningen filtreres og fordampes til tørrhet. Residuet kromatograferes på 50 g silikagel, eluering med 60:40:1 hexan:etylacetat:maursyre, 1.38 g of 2-(5H-dibenzo(a,djcyclohepten-5-on-2-yl)-acrylic acid is dissolved in 25 ml of dimethylformamide containing 0.05 S 5 fo palladium on charcoal catalyst. The mixture is stirred in a hydrogen atmosphere at 26°C and jSf mm Hg pressure' until 60 ml (1 molar equivalent) has been absorbed. The solution is filtered and evaporated to dryness. The residue is chromatographed on 50 g of silica gel, eluting with 60:40:1 hexane:ethyl acetate:formic acid,
slik at man får et 40 f° utbytte av 2-(5H-dibenzofa,djcyklohepten-5-on-2-yl)propionsyre, smeltepunkt (kloroform-hexan) 138-139°C; smeltepunkt (aceton-hexan) 113-115°C. so that a 40 f° yield of 2-(5H-dibenzopha,djcyclohepten-5-on-2-yl)propionic acid is obtained, melting point (chloroform-hexane) 138-139°C; melting point (acetone-hexane) 113-115°C.
Anvendelse av metyl 2-(5H-dibenzo[a,dJcyklohepten-5-on-2-yl)acrylat gir et tilsvarende utbytte av metyl 2-(5H-dibenzo[a,dJcyklohepten-5-on-2-yl)propionat som en olje som kry-stalliserer langsomt med smeltepunkt 37-39°C« Use of methyl 2-(5H-dibenzo[a,dJcyclohepten-5-on-2-yl)acrylate gives a similar yield of methyl 2-(5H-dibenzo[a,dJcyclohepten-5-on-2-yl)propionate which an oil that crystallizes slowly with a melting point of 37-39°C"
Anvendelse av natrium 2-(5H-dibenzo(a,dJcyklohepten-5-on-2-yl)acrylat gir et tilsvarende utbytte av natrium 2-(5H-dibenzofa,djcyklohepten-5-on-2-yl)propionat, smeltepunkt 145-148°C. Use of sodium 2-(5H-dibenzo(a,dJcyclohepten-5-on-2-yl)acrylate gives a corresponding yield of sodium 2-(5H-dibenzopha,djcyclohepten-5-on-2-yl)propionate, melting point 145 -148°C.
Claims (2)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US61105275A | 1975-09-08 | 1975-09-08 |
Publications (1)
Publication Number | Publication Date |
---|---|
NO753413L true NO753413L (en) | 1977-03-09 |
Family
ID=24447430
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO753413A NO753413L (en) | 1975-09-08 | 1975-10-09 |
Country Status (4)
Country | Link |
---|---|
DK (1) | DK468875A (en) |
FI (1) | FI752875A (en) |
NO (1) | NO753413L (en) |
SE (1) | SE7510941L (en) |
-
1975
- 1975-09-30 SE SE7510941A patent/SE7510941L/en unknown
- 1975-10-09 NO NO753413A patent/NO753413L/no unknown
- 1975-10-15 FI FI752875A patent/FI752875A/fi not_active Application Discontinuation
- 1975-10-17 DK DK468875A patent/DK468875A/en unknown
Also Published As
Publication number | Publication date |
---|---|
FI752875A (en) | 1977-03-09 |
DK468875A (en) | 1977-03-09 |
SE7510941L (en) | 1977-03-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA1127165A (en) | Dibenzothiepin derivatives and a process for producing the same | |
SU511848A3 (en) | Method for producing substituted benzoylphenyl-3-butenoic acid | |
DE2224655A1 (en) | Tricyclic compounds and processes for their preparation | |
NO753413L (en) | ||
US4337353A (en) | Novel carboxylic acids, benzoyl phenyl alkanoic acids and use thereof | |
US3663627A (en) | 1-indanmethanols | |
SU1039439A3 (en) | Process for preparing 2-(3-phenoxyphenyl)-proprionic acid or its calcium salt | |
US2701251A (en) | Process of producing indoleacetic acids and new indoleacetic acids produced thereby | |
US4116972A (en) | Anti-inflammatory 1-oxo-isoindoline derivatives and processes for their preparation | |
NO753416L (en) | ||
NO753411L (en) | ||
US4264773A (en) | Preparation of 2-chloro-thioxanthone | |
JPS6031823B2 (en) | Method for producing carbazole derivatives | |
US4690945A (en) | Process for the preparation of 5'-substituted 2-(3'-thienyl)propionic acids | |
Hannoun et al. | alpha‐phenylpropionic acid derivatives. Synthesis and dethiation of 5‐benzoylbenzo [b] thiophene‐3‐carboxylic acid | |
Mowry et al. | Vinyl Aromatic Compounds. V. Ortho-, Meta-and Para-Isopropenylbiphenyls1 | |
NO743135L (en) | ||
US3860659A (en) | 5-Fluoro-2-methyl 1-(4{40 -methylsulfinylbenzylidene)-3-indenyl ethanol | |
NO753417L (en) | ||
US4011241A (en) | An intermediate in the preparation of 2-(5H-dibenzo[a,d]cyclophepten-5-on-2-yl)acetic, propionic and butyric acids | |
US2537892A (en) | Esters of 2-benzamido-3-carboxymethylmercapto-propanoic acid | |
NO131507B (en) | ||
US4038299A (en) | 2-Substituted-5-oxo-5H-dibenzo [a,d] -cycloheptene esters | |
US4059611A (en) | Oxidative process for the preparation of 2-(5H-dibenzo[a,d]cyclohepten-5-on-2-yl)acetic, propionic and butyric acid | |
KR790001825B1 (en) | Process for preparing stilbene derivatives |